Comparative Pharmacology
Head-to-head clinical analysis: OMNIPAQUE 12 versus OMNIPAQUE 140.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMNIPAQUE 12 versus OMNIPAQUE 140.
OMNIPAQUE 12 vs OMNIPAQUE 140
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Radiopaque agent that attenuates X-rays, providing contrast in imaging. Iodine atoms absorb X-rays, enhancing visualization of blood vessels and tissues.
Radiopaque contrast agent that attenuates X-rays due to iodine content, enhancing vascular and tissue visualization.
Adult dose: 12 g iodine (e.g., 200 mL of Omnipaque 12) administered intravenously, intra-arterially, or into body cavities. Typical contrast study dose: 1-2 mL/kg (max 150 mL) for CT; 40-60 mL for angiographic procedures.
Intravascular: 50-200 mL (containing 7.0-28.0 g iodine) per procedure, administered intravenously as a bolus or infusion; dose depends on imaging modality and body region. Intrathecal: 6-15 mL (containing 0.84-2.1 g iodine) administered via lumbar puncture for myelography.
None Documented
None Documented
1-2 hours (normal renal function); prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min)
Terminal elimination half-life: 1–2 hours; prolonged in renal impairment (up to 30–40 hours in severe dysfunction).
Renal: >95% unchanged; biliary/fecal: <5%
Renal: >95% unchanged via glomerular filtration; biliary/fecal: negligible (<1%).
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent